Latest News

  • Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer Read More
  • Alkermes to Take Part in Stifel's 3rd Annual CNS Day Read More
  • Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy Read More
  • Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma Read More

Investors